Industry veteran Mel Routhier will lead VML Health’s global creative team with the new appointments of Khalid Latif as global executive creative director (Europe), VML Health and Natxo Diaz as global head of health craft, VML Health.
Three general manager positions and one vice president position mark the latest career advancements at the fast-growing company.
As part of his appointment to the role of COO, Valdez will work directly with Elizabeth Apelles, CEO of Greater Than One, to align the agency with a renewed shared vision, along with clear goals for growth and innovation.
Med Ad News spoke with Marcia Goddard on Day Three of her new role as chief creative officer at RevHealth, and she was definitely energized and excited about the transformation RevHealth has been undergoing – a new branding and vision, and changes to the leadership team.
It was last year’s hottest topic, and this year it is sure to be at the top of the list. It dominates conversations, and it sure does dominate my inbox. Artificial intelligence.
Excitement is mounting across the industry going into 2024 about data and digital innovations’ potential for improving engagement among consumers, patients, and caregivers. That excitement is evident in conversations with eight industry leaders who are embracing digital to advance personalization, support health equity, and reach patients on new channels.
In 2024, the industry must acknowledge the interconnected impact of the Inflation Reduction Act (IRA), growing AI and technology usage, and evolving smart data, as these factors create a ripple effect. How market access responds to these effects will impact sales and marketing. Effectively addressing these impacts lies at the heart of industry reform.
Pharma commercial leaders are understandably energized by the prospect of leveraging emerging technology (e.g., advanced AI tools) to amplify the velocity and impact of their promotional efforts. While this potential lies ahead, commercial leaders must first address the age-old organizational challenges that continue to stand in the way of a fully coordinated and customer-centric promotional infrastructure.
We at Med Ad News don’t claim to know all the questions. So we challenged our contributors to come up with their own questions and answer them.
Even as they are gathering proof of extensive benefits to patients, the manufacturers of GLP-1s will have to overcome supply chain difficulties and high prices to get payers to fund these medicines for treating obesity.